Cutaneous Manifestations Of Inflammatory Bowel Disease

##plugins.themes.academic_pro.article.sidebar##

Published May 26, 2010
Download
pdf
Vol. 88 No. 6 (2010): Issue Jun 2010

##plugins.themes.academic_pro.article.main##

Leila Mnif
Ali Amouri
Nabil Tahri
Department of gastroenterology University Hospital Hedi Chaker Sfax Tunisia

Abstract

Background : Cutaneous manifestations are relatively common complications of inflammatory bowel disease, although they vary widely. At the time of inflammatory bowel disease diagnosis, the mean incidence of these manifestations is around 10%.
The aim of this article was to review some of the noteworthy skin disorders associated with inflammatory bowel disease.
Methods: An electronic research of the medical literature was carried out on the web sites “PubMed”, “ScienceDirect” and “Interscience Wiley”.
Results: The cutaneous manifestations associated with inflammatory bowel disease were divided into 3 groups based on the nature of the association: granulomatous cutaneous disease, reactive skin eruptions and other associated dermatoses. In this review, focus has been given on granulomatous cutaneous disease and reactive skin eruptions.
Conclusion: Patients presenting with inflammatory bowel disease should be examined for cutaneous manifestations. For most of these cutaneous manifestations, the primary therapeutic target remains the bowel.

Keywords:

Granulomatous cutaneous lesions, Reactive skin eruptions, inflammatory bowel disease, Crohn's disease, Ulcerative colitis

##plugins.themes.academic_pro.article.details##

References

  1. Tavarela Veloso F. Review article: skin complications associated with inflammatory bowel disease. Aliment Pharmacol Ther 2004; 20: 50-3.
  2. Tavarela Veloso F, Carvalho S, Magro F. Immune-related systemic manifestations of inflammatory bowel disease. A prospective study of 792 patients. J Clin Gastroenterol 1996; 23: 29 -34.
  3. Rankin GB, Watts HD, Melnyk CS, et al. National Cooperative Crohn's Disease Study: extraintestinal manifestations and perianal complications. Gastroenterology 1979; 77: 914- 20.
  4. Jones J, Tremaine W. Evaluation of perianal fistulas in patients with crohn's disease. MedGenMed 2005; 7: 16.
  5. Sandborn WJ, Fazio VW, Feagan BG, et al. AGA technical review on perianal crohn's disease. Gastroenterology 2003; 125: 1508 - 30.
  6. Asquith P, Thompson RA, Cooke WT. Oral manifestations of crohn's disease. Gut 1975; 16: 249 -54.
  7. Moravvej H, Razavi GM, Farshchian M, et al. Cutaneous manifestations in 404 Iranian patients with inflammatory bowel disease: A retrospective study. Indian J Dermatol Venereol Leprol 2008; 74: 607 - 10.
  8. Shller KFR, Golding P-L, Peebles RA, et al. Crohn's disease of the mouth and lips. Gut 1971; 12: 864.
  9. MacPhail L. Topical and systemic therapy for recurrent aphthous stomatitis. Seminars Cutaneous Medicine and Surgery 1997; 16: 301 - 7.
  10. Cardoso H, Nunes AC, Carneiro F, et al. Successful Infliximab therapy for oral crohn's disease. Inflamm Bowel Dis 2006; 12: 337 - 8.
  11. Calobrisi S, Mutasim D, McDonald J. Pyostomatitis vegetans associated with ulcerative colitis: temporary clearance with fluocinonide gel and complete remission after colectomy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1995; 79: 452 -4.
  12. Storwick G, Prihoda M, Fulton R, et al. Pyodermatitis -pyostomatitis vegetans: a specific marker for inflammatory bowel disease. J Am Acad Dermatol 1994; 31: 336 - 41.
  13. Brinkmeier T, Frosch PJ. Pyodermatitis - pyostomatitis vegetans: A clinical course of two decades with response to cyclosporine and low - dose prednisolone. Acta Derm Venereol 2001; 81: 134 - 6.
  14. Berkowitz EZ, Lebwohl M. Cutaneous manifestations of inflammatory bowel disease. JEADV 2000; 14: 349 - 50.
  15. Lebwohl M, Lebwohl O. Cutaneous manifestations of inflammatory bowel disease. Inflamm Bowel Dis 1998; 4: 142 - 8.
  16. Kafity AA, Pellegrini AE, Fronkes JJ. Metastatic crohn's disease.A rare cutaneous manifestation. J Clin Gastroenterol 1993; 17: 300 - 3.
  17. Van Dullemen H, De Jong E, Slors F, et al. Treatment of therapy - resistant perianal metastatic crohn's disease after protectomy using anti-tumor necrosis factor chimeric monoclonal antibody, cA2: report of two cases. Dis Colon Rectum 1998; 41: 98 - 102.
  18. Apgar JT. Newer aspects of inflammatory bowel disease and its cutaneous manifestations: a selective review. Semin Dermatol 1991; 10: 138 - 47.
  19. Trost LB, McDonnell JK. Important cutaneous manifestations of inflammatory bowel disease. Postgrad Med J 2005; 81: 580 - 5.
  20. Fleisher M, Rubin S, Levine A, et al. Infliximab in the treatment of steroid refractory erythema nodosum of IBD. Gastroenterology 2002; 122 (Suppl. 1): A 618 (Abstract).
  21. Brooklyn T, Dunnill G, Probert C. Diagnosis and treatment of pyoderma gangrenosum. BMJ 2006; 333: 181 - 4.
  22. Brooklyn T, Dunnill GS, Shetty A, et al. Infliximab for the treatment of pyoderma gangrenosum: a randomized, double - blind placebo - controlled trial. Gut 2006; 55: 505 - 9.
  23. Ardizzone S, Sarzi Puttini P, Cassinotti A, et al. Extraintestinal manifestations of inflammatory bowel disease. Dig Liver Dis 2008; 40 (Suppl. 2): S 253 - 9.
  24. Cohen AD, Dreiher J, Birkenfeld S. Psoriasis associated with ulcerative colitis and crohn's disease. J Eur Acad Dermatol Venereol 2009; 23 : 561 - 5.
  25. Lee FI, Bellary SV, Francis C. Increased occurrence of psoriasis in patients with crohn's disease and their relatives. Am J Gastroenterol 1990; 85: 962 - 3.